Literature DB >> 11918532

Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia.

Maria Messinezy1, Nigel B Westwood, Ihab El-Hemaidi, Joanne T Marsden, Roy S Sherwood, Thomas C Pearson.   

Abstract

Serum erythropoietin (Epo) values were estimated in samples from 125 patients with erythrocytosis to examine the specificity and sensitivity of reduced and raised values in the diagnosis of polycythaemia vera (PV) and secondary erythrocytosis (SE) respectively. Additionally, Epo values were estimated in samples from 49 patients with primary thrombocythaemia (PT) to determine whether Epo values were altered. We found high specificity (92%) and moderate sensitivity (64%) of low serum Epo values (below the reference range) in the diagnosis of PV, and also poor sensitivity (47%) of raised Epo values in the diagnosis of SE. Raised Epo values were not observed in PV patients with Hb > 14.0 g/dl and were only observed in one PV patient with a relatively low Hb recovering from a gastro-intestinal haemorrhage. Raised Epo values occurred in some patients with apparent erythrocytosis (AE) and idiopathic erythrocytosis (IE), mainly at normal (rather than raised) Hb values (< 16 g/dl). Low Epo values occurred in a few AE, IE and SE patients at higher Hb values (> 16 g/dl). Low Epo values were less specific for PV when the Hb was raised, while raised Epo values were less specific for SE when the Hb was not raised. Approximately one third of patients with PT had a low (below the reference range) Epo value, this being associated with a high normal Hb (> 14 g/dl, P < 0.001) and showing a trend towards association with absence of treatment. The high normal Hb values were in turn associated with an increased incidence of thrombotic events (P < 0.05). These findings could influence the future investigation and management of PT patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918532     DOI: 10.1046/j.1365-2141.2002.03386.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.

Authors:  Alberto Alvarez-Larrán; Agueda Ancochea; Anna Angona; Carme Pedro; Francesc García-Pallarols; Luz Martínez-Avilés; Beatriz Bellosillo; Carlos Besses
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 2.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 3.  Investigation and management of erythrocytosis.

Authors:  Siraj Mithoowani; Marissa Laureano; Mark A Crowther; Christopher M Hillis
Journal:  CMAJ       Date:  2020-08-10       Impact factor: 8.262

Review 4.  A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F).

Authors:  Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

5.  Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome.

Authors:  Catherine Jones; Yair Levy; Alex W Tong
Journal:  BMJ Case Rep       Date:  2014-12-01

Review 6.  Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.

Authors:  Martha Wadleigh; Ayalew Tefferi
Journal:  Int J Hematol       Date:  2010-02-27       Impact factor: 2.490

7.  Clinical Characteristics of Pediatric Patients with Congenital Erythrocytosis: A Single-Center Study.

Authors:  Sema Aylan Gelen; Nazan Sarper; Emine Zengin; İnci Tahsin; Mehmet Azizoğlu
Journal:  Indian J Hematol Blood Transfus       Date:  2021-08-25       Impact factor: 0.900

Review 8.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

Review 9.  Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients.

Authors:  Jan Jacques Michiels
Journal:  World J Crit Care Med       Date:  2015-08-04

Review 10.  Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Authors:  Ayalew Tefferi; Radek Skoda; James W Vardiman
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.